Abbott Laboratories
ABT106.090USD
+0.040+0.04%
Handelsschluss 01/29, 16:00（ET）Kurse um 15 Minuten verzögert
184.48BMarktkapitalisierung
28.44KGV TTM
mehr Informationen über Abbott Laboratories Unternehmen
Abbott Laboratories ist ein US‑amerikanisches multinationales Unternehmen im Gesundheits‑ und Medizintechnik‑Sektor mit Hauptsitz in Abbott Park (Illinois). Gegründet 1888 von Dr. Wallace Calvin Abbott in Chicago, spezialisierte sich das Unternehmen zunächst darauf, wirksame Arznei‑Bestandteile in präzisen Dosierungen bereitzustellen. Heute produziert Abbott medizinische Geräte, Diagnostika, Marken‑Generika sowie Spezialnahrung für unterschiedliche Ernährungsbedürfnisse. 2013 gliederte Abbott seine forschungsorientierte Pharmasparte aus; sie firmiert seitdem als AbbVie.
Zu den bekannten Abbott‑Marken zählen Pedialyte (orale Rehydratationslösung), Similac (Säuglingsnahrung), BinaxNOW (COVID‑19‑Antigen‑Schnelltest), Ensure (hochkalorische Trinknahrung), Glucerna (Diätnahrung für Diabetiker), ZonePerfect (Protein‑ & Energieriegel), FreeStyle Libre (kontinuierliches Glukosemesssystem), i‑STAT (tragbares Blutanalysegerät) und MitraClip (minimal‑invasives Mitralklappen‑Implantat).
Abbott Laboratories Informationen
BörsenkürzelABT
Name des UnternehmensAbbott Laboratories
IPO-datumApr 06, 2073
CEOFord (Robert B)
Anzahl der mitarbeiter114000
WertpapierartOrdinary Share
GeschäftsjahresendeApr 06
Addresse100 Abbott Park Road
StadtABBOTT PARK
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl60064-3500
Telefon12246676100
Websitehttps://www.abbott.com
BörsenkürzelABT
IPO-datumApr 06, 2073
CEOFord (Robert B)
Führungskräfte von Abbott Laboratories
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+1635.00%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
132.23K
-1536.00%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-791.00%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-269.00%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
50.97K
-387.00%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
40.80K
+1635.00%
Ms. Sally E. Blount, Ph.D.
Ms. Sally E. Blount, Ph.D.
Independent Director
Independent Director
34.06K
-965.00%
Mr. John G. Stratton
Mr. John G. Stratton
Independent Director
Independent Director
19.03K
+1635.00%
Ms. Michelle A. Kumbier
Ms. Michelle A. Kumbier
Independent Director
Independent Director
15.71K
+1635.00%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+1635.00%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
132.23K
-1536.00%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-791.00%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-269.00%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
50.97K
-387.00%
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Diabetes Care
2.06B
18.09%
Core Laboratory
1.36B
12.00%
Structural Heart
1.28B
11.23%
Adult Nutritionals
1.18B
10.34%
Key Emerging Markets
1.10B
9.65%
Andere
4.40B
38.68%
Nach RegionUSD
Name
Umsatz
Anteil
All other Countries
7.07B
62.19%
United States
4.30B
37.81%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Diabetes Care
2.06B
18.09%
Core Laboratory
1.36B
12.00%
Structural Heart
1.28B
11.23%
Adult Nutritionals
1.18B
10.34%
Key Emerging Markets
1.10B
9.65%
Andere
4.40B
38.68%
Aktionärsstatistik
Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.05%
BlackRock Institutional Trust Company, N.A.
5.13%
State Street Investment Management (US)
4.50%
Capital International Investors
3.54%
Capital Research Global Investors
2.23%
Andere
74.55%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.05%
BlackRock Institutional Trust Company, N.A.
5.13%
State Street Investment Management (US)
4.50%
Capital International Investors
3.54%
Capital Research Global Investors
2.23%
Andere
74.55%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
47.26%
Investment Advisor/Hedge Fund
23.11%
Research Firm
3.51%
Pension Fund
2.34%
Bank and Trust
2.20%
Sovereign Wealth Fund
1.37%
Insurance Company
1.02%
Hedge Fund
0.49%
Individual Investor
0.48%
Andere
18.22%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
4606
1.42B
81.82%
+3.92M
2025Q3
4681
1.42B
81.87%
+8.53M
2025Q2
4668
1.41B
81.51%
+6.23M
2025Q1
4636
1.40B
80.10%
+7.18M
2024Q4
4554
1.38B
78.81%
+33.68M
2024Q3
4367
1.35B
78.83%
-5.95M
2024Q2
4376
1.35B
78.36%
+5.03M
2024Q1
4375
1.35B
77.56%
-1.86M
2023Q4
4400
1.34B
77.62%
+7.10M
2023Q3
4258
1.33B
78.26%
-4.16M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
174.89M
10.06%
+2.54M
+1.47%
Nov 28, 2025
BlackRock Institutional Trust Company, N.A.
89.23M
5.13%
+711.43K
+0.80%
Sep 30, 2025
State Street Investment Management (US)
78.23M
4.5%
-128.28K
-0.16%
Sep 30, 2025
Capital International Investors
61.61M
3.54%
+1.48M
+2.46%
Sep 30, 2025
Capital Research Global Investors
38.77M
2.23%
-3.00M
-7.18%
Sep 30, 2025
Geode Capital Management, L.L.C.
38.54M
2.22%
+248.83K
+0.65%
Sep 30, 2025
Wellington Management Company, LLP
23.25M
1.34%
-1.80M
-7.20%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
22.25M
1.28%
+1.27M
+6.03%
Jun 30, 2025
JP Morgan Asset Management
19.25M
1.11%
-7.14M
-27.05%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
17.77M
1.02%
+9.40M
+112.38%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Nov 5
Aktualisiert: Wed, Nov 5
Name
Anteil
iShares U.S. Medical Devices ETF
19.31%
Goldman Sachs Future Health Care Equity ETF
6.26%
SMI 3Fourteen Full-Cycle Trend ETF
5.01%
Invesco Pharmaceuticals ETF
4.99%
Health Care Select Sector SPDR Fund
4.62%
Proshares Ultra Health Care
4.61%
Tema Heart & Health ETF
4.5%
iShares U.S. Healthcare ETF
4.42%
AdvisorShares Focused Equity ETF
4.37%
Polen Capital Global Growth ETF
4.27%
Mehr Anzeigen
iShares U.S. Medical Devices ETF
Anteil19.31%
Goldman Sachs Future Health Care Equity ETF
Anteil6.26%
SMI 3Fourteen Full-Cycle Trend ETF
Anteil5.01%
Invesco Pharmaceuticals ETF
Anteil4.99%
Health Care Select Sector SPDR Fund
Anteil4.62%
Proshares Ultra Health Care
Anteil4.61%
Tema Heart & Health ETF
Anteil4.5%
iShares U.S. Healthcare ETF
Anteil4.42%
AdvisorShares Focused Equity ETF
Anteil4.37%
Polen Capital Global Growth ETF
Anteil4.27%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
13.90B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Dec 12, 2025
ABT.NB Final Cash Dividend of gross USD 0.63 paid on Feb 13, 2026 going ex on Jan 15, 2026 with reinvestment option
Jan 15, 2026
Feb 13, 2026
Jan 15, 2026
Sep 19, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Nov 17, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 17, 2025
Oct 15, 2025
Jun 13, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 21, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Dec 13, 2024
ABT.NB Final Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 19, 2024
ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 15, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 16, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Dec 15, 2023
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option
Jan 12, 2024
Feb 15, 2024
Jan 11, 2024
Sep 21, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Mehr Anzeigen
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
